Quantcast

Latest Bioethics Stories

2014-04-16 16:30:19

TORONTO, April 16, 2014 /CNW/ - Ontario's doctors are helping to mark Advance Care Planning Day today by encouraging everyone to take a moment and consider their end-of-life wishes. Advance care planning starts with thinking about your wishes, values and beliefs about the health care you would want if you were ever incapable of making decisions for yourself, and then talking about them with loved ones. "A medical crisis is always going to be a terrible time for a family, but having simple...

2014-04-16 00:21:06

TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American...

2014-04-15 12:30:30

BOSTON, April 15, 2014 /PRNewswire-USNewswire/ -- Boston City Council Committee on Government Operations, chaired by Councilors Michael Flaherty & Tito Jackson, to conduct April 16 hearing on Docket #0227, An Ordinance Regarding the Prohibition of Research Designated as Biosafety Level 4, Sponsored by Councilors Charles Yancey, Tito Jackson & Ayanna Pressley. http://photos.prnewswire.com/prnvar/20140415/73231 Community residents, scientific experts and civic advocates to...

2014-04-02 23:33:55

New study by researchers Dr. Eric Finzi and Dr. Norman E. Rosenthal published in the Journal of Psychiatric Research May 2014 edition reports that patients injected with onabotulinumtoxinA demonstrated substantial improvement - 52% - in their depressive symptoms. Washington, DC (PRWEB) April 02, 2014 In the largest randomized, double-blind, placebo controlled study to date on the effect of OnabotulinumtoxinA (known as Botox) on depression, researchers found that more than half of subjects...

2014-04-01 23:23:22

Dr. Beverly Davidson Researches Novel Treatments for Neurological Diseases Philadelphia, PA (PRWEB) April 01, 2014 Beverly L. Davidson, Ph.D., a nationally prominent expert in gene therapy, is joining The Children’s Hospital of Philadelphia (CHOP) today. Dr. Davidson, who investigates gene therapy for neurodegenerative diseases, arrives from the Center for Gene Therapy at the University of Iowa. She served as associate director at that Center, as well as director of the Gene Therapy...

2014-04-01 20:21:49

DUBLIN, April 2, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pttfr4/cancer_gene) has announced the addition of the "Cancer Gene Therapy Market Analysis" [http://www.researchandmarkets.com/research/pttfr4/cancer_gene ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The gene therapy market has undergone series of transformation from the initial days of research to current clinical...

2014-03-31 08:29:05

MELBOURNE, Australia, March 31, 2014 /PRNewswire/ -- Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results. Prana's PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer's disease patients, as measured using PiB-PET Standardized Uptake Value...

2014-03-22 08:21:21

- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2) EAST HANOVER, N.J., March 22, 2014 /PRNewswire/ -- Novartis today announced results from the Phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response...

2014-03-20 23:03:41

BioFire Defense of Salt Lake City, Utah announced today that it was awarded the Next Generation Diagnostic System (NGDS) Technology Development contract by the US Department of Defense. Salt Lake City, UT (PRWEB) March 20, 2014 BioFire Defense, LLC of Salt Lake City, UT announced today that it was awarded the Next Generation Diagnostic System (NGDS) Technology Development contract by the US Department of Defense (DoD) after 12 months of competitive prototyping. The 8 year $240M biodefense...

Multiple Sclerosis May Benefit From Statins
2014-03-19 10:09:06

Brett Smith for redOrbit.com - Your Universe Online At first, multiple sclerosis is recognized by sporadic neurological symptoms – a condition called relapsing-remitting MS. Within a decade or so, greater than 50 percent of patients acquire secondary progressive MS, a continuous deterioration of symptoms and boost in disability. Currently, there are no approved drugs for treating this later stage of the disease. However, a newly published study in the UK medical journal The Lancet has...


Latest Bioethics Reference Libraries

OncoMouse
2013-10-02 09:29:43

The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...

More Articles (1 articles) »
Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related